Wolfe Research initiated coverage of Rapt Therapeutics with an Outperform rating and $39 price target. In the past year, the stock has underperformed largely due to an enrollment delay and the lack of major catalysts in 2023, the analyst tells investors in a research note. The firm believes the stock will have multiple opportunities to outperform in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RAPT: